OncoMatch/Clinical Trials/NCT04485286
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Is NCT04485286 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies [68Ga]CBP8 for lung cancer.
Treatment: [68Ga]CBP8 — The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Disease stage
Required: Stage I, II, III, IIIA
Lab requirements
Kidney function
eGFR of less than 30 mL/min/1.73 m2 within the past 90 days [excluded]
eGFR of less than 30 mL/min/1.73 m2 within the past 90 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify